Compare
Immuneering Corp vs Oramed Pharmaceuticals Inc. vs Design Therapeutics, Inc. vs Evolus, Inc.
| Latest fiscal year | Immuneering Corp IMRX | Oramed Pharmaceuticals Inc. ORMPRevenue covers only part of its income (partial revenue) | Design Therapeutics, Inc. DSGN | Evolus, Inc. EOLS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $297.18M |
| Revenue growth (YoY) | n/a | n/a | n/a | +11.6% |
| Gross margin | n/a | n/a | n/a | 66.3% |
| Operating margin | n/a | n/a | n/a | -11.0% |
| Net margin | n/a | n/a | n/a | -17.4% |
| Net income | -$56.02M | $64.05M | -$69.79M | -$51.64M |
| EPS (Diluted) | -$1.27 | $1.50 | -$1.22 | -$0.80 |
| Operating cash flow | -$45.34M | -$9.14M | -$54.36M | -$42.27M |
| Free cash flow | -$45.49M | -$9.15M | -$54.55M | -$45.71M |
| Cash & equivalents | $128.65M | $45.95M | $16.86M | $53.83M |
| Total assets | $231.99M | $230.86M | $226.20M | $225.87M |
| Total liabilities | $13.50M | n/a | $13.70M | $248.97M |
| Shareholders' equity | $218.48M | $199.74M | $212.50M | -$23.11M |
| Return on year-end equity | -25.6% | 32.1% | -32.8% | n/a |
| Shares outstanding | n/a | 39.28M | 60.40M | 65.01M |
Revenue, most recent five fiscal years
| Fiscal year | Immuneering Corp | Oramed Pharmaceuticals Inc. | Design Therapeutics, Inc. | Evolus, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | n/a | $0 Ended 2025-12-31 | $297.18M Ended 2025-12-31 |
| 1 year earlier | $317.0K Ended 2022-12-31 | n/a | $0 Ended 2024-12-31 | $266.27M Ended 2024-12-31 |
| 2 years earlier | $2.08M Ended 2021-12-31 | n/a | n/a | $202.09M Ended 2023-12-31 |
| 3 years earlier | $2.31M Ended 2020-12-31 | n/a | n/a | $148.62M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $99.67M Ended 2021-12-31 |